Elan buys share of Theravance royalties on new drug for $1B; Vivus bulks up its board in anticipation of proxy fight;

Two businessmen shaking hands in a hallway

@FiercePharma: FDA nixes Endo petition to protect Opana ER from generics. Article | Follow @FiercePharma

> Irish drugmaker Elan ($ELN) snapped up a 21% share of Theravance ($THRX) royalties on a newly approved respiratory drug to be sold by GlaxoSmithKline ($GSK) in a $1 billion deal aimed at strengthening its defense against a buyout bid by Royalty Pharma. Report

> Vivus ($VVUS), under pressure from investors unhappy with its obesity drug marketing, has added two more directors to its board at a time when shareholder First Manhattan has proposed its own slate of 6 nominees. Report

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

> Two North Dakota men joined the hundreds who have sued Takeda Pharmaceutical, claiming the company's diabetes drug Actos caused their bladder cancer. Report

> GlaxoSmithKline and Save the Children teamed up in a 5-year, $23 million deal to improve healthcare and vaccination in the developing world. Report

Medical Device News

@FierceMedDev: Boston Scientific's Watchman AF device generates more stunning data. Story | Follow @FierceMedDev

@MarkHFierce: Swiss stent maker Bioensors Int'l will pay $51M for a U.S. imaging company - diversification program now under way. More | Follow @MarkHFierce

 @DamianFierce: Glaxo is reaching into Hong Kong with a new DKSH partnership, targeting antibiotics. Article | Follow @DamianFierce

> Israel's budding medical device industry begins to flower. Item

> Sorin wins FDA nod for cardiac monitor. News

> Michigan State develops blood Dx for childhood malaria complication. DxExtra

Biotech News

@FierceBiotech:  FDA accepts $BIIB's BLA for 1st long-lasting factor VIII therapy for hemophilia A. Release | Follow @FierceBiotech

@JohnCFierce: J&J gets a priority review for hep C drug simeprevir (with Medivir). More | Follow @JohnCFierce

@RyanMFierce:  Mobile service PharmaSecure finds demand in losing fight against fake drugs. Story | Follow @RyanMFierce

> Vectura joins forces with a new JV biotech in China for respiratory therapies. News

> Class action suits pile up at Aveo's doorstep in wake of FDA debacle. More

> Elan pays $1B for a slice of Theravance's COPD franchise royalty stream. News

CRO News

> Argentine CRO Stat Research taps Datatrak. News

> Harlan Labs doubles in specialty research with U.S. expansion. Story

> PRA boosts informatics with Welsh expansion. More

> Quintiles hauls in $947M IPO after upping offering. Report

> AMRI piles on profits with strong Q2. Article

Biotech IT News

> Pfizer tests online Viagra sales to beat the cheats. News

> IT outfit Instem acquires Logos to penetrate early clinical trials market. More

> GlaxoSmithKline exec details expectations for online clinical trial research. Article

> Hong Kong billionaire backs Big Data effort in biomedicine at Oxford University. Story

> Pfizer opts to keep running Accelrys software in its labs. Article

And Finally... Scientists found a biomarker in patients' noses that may be linked to schizophrenia. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.